Indication

Neulasta® is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer
(non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low white blood cell count.

Neulasta® is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low white blood cell count.

Neulasta® is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low white blood cell count.

You are now leaving Neulasta.com

The sponsors of this site are not responsible for content on the site you are about to enter.

You are going to a website that contains clinical information and was created specifically for healthcare professionals. If you are not a healthcare professional and would like to return to the consumer site, please click CANCEL.

Whether you’re a patient or caregiver,
these tools can help.


Questions about Neulasta® or Neulasta® Onpro®?
Call us toll-free at 1-844-MYNEULASTA
(1-844-696-3852)

Questions? Call us toll-free 1-844-MYNEULASTA
(1-844-696-3852)

With Neulasta FIRST STEP®, eligible commercially insured patients could pay $5 or less per dose.

See below for eligibility
requirements and coverage limits.

Wondering about the cost
of Neulasta® Onpro®?

  • The Neulasta FIRST STEP® Program

    The Neulasta FIRST STEP® program* can help you reduce out-of-pocket costs for your
    Neulasta® or Neulasta® Onpro® prescription if you purchase
    your own insurance plan or
    receive one through your job.

    • No out-of-pocket cost for the first dose

    • No income eligibility requirement

    • For subsequent doses, Amgen will pay the out-of-pocket amount
      in excess of $5 per dose, up to $10,000 in assistance per calendar year.

    Visit www.NeulastaFIRSTSTEP.com to find out more!
    Or call 1-888-657-8371 for more information.

    Patient Eligibility Requirements:

    Patient must be prescribed Neulasta®

    Must have private commercial health insurance that covers medication costs for Neulasta® or Neulasta® Onpro®

    Not a participant in any federal-, state-, or government-funded healthcare program such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TriCare

    Patients may not seek reimbursement for value received from the Amgen FIRST STEP® Program from any third-party payers, including flexible spending accounts or healthcare savings accounts. If at any time patients begin receiving coverage under any federal-, state-, or government-funded healthcare program, patients will no longer be eligible to participate in the Amgen FIRST STEP® Program and must call 1-888-65-STEP1 (1-888-657-8371) Monday through Friday, 9 AM-8 PM EST to stop participation. Restrictions may apply. Amgen reserves the right to revise or terminate this program, in whole or in part, without notice at any time. This is not health insurance.

    *Other restrictions apply. Not valid where prohibited by law. Amgen reserves the right to revise or terminate this program, in whole or part, without notice at any time.

    Coverage Limits:

    Program covers out-of-pocket medication costs for the Amgen product only. Program does not cover any other costs related to office visit or administration of the Amgen product.

    No out-of-pocket cost for first dose or cycle; $5 out-of-pocket cost for subsequent dose or cycle; for Neulasta® (pegfilgrastim) and Neulasta® Onpro®, maximum benefit of $10,000 per patient per calendar year. Patient is responsible for costs above this amount.

    Ongoing activation of the Amgen FIRST STEP® card is contingent on the submission of the required Explanation of Benefits (EOB) form by the healthcare provider's office within 45 days of use of the Amgen FIRST STEP® card. Patients will be responsible for reimbursing the program for all amounts paid out if the EOB for the date of service is not received within 45 days.

  • Amgen Assist 360

    Whatever insurance you have—even if you have none—Amgen 360 can help you understand how your Amgen medicine may be covered and refer you to programs that may be able to help you afford it, such as Neulasta FIRST STEP® or other independent nonprofit organizationsb.

    bResources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

card

Find Support in the Cancer Community

There are organizations all over the country that can provide information and support during your cancer journey and beyond.* Start here to find resources in your area.

*These third party resources are for your information only. Amgen does not endorse and is not responsible for the content included in these resources.

American Cancer Society® (ACS)

News, information, and support.

Phone (toll-free): 800-227-2345

www.cancer.org

Cancer Hope Network

National, nonprofit organization offering free and confidential one-on-one emotional support to adult patients with cancer and their families.

Phone (toll-free): 1-877-467-3638

www.cancerhopenetwork.org

Cancer Support Community®

Support, education, and researh for people living with cancer.

Phone: 202-659-9709 or toll-free 888-793-9355

www.cancersupportcommunity.org

National Cancer Institute (NCI)

The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training.

Phone (toll-free): 800-4-CANCER (800-422-6237)

www.cancer.gov

National Comprehensive Cancer Network® (NCCN®)

Alliance of leading cancer centers that offers patient education resources and assistance information, including disease-specific treatment guidelines.

Phone: 215-690-0300

www.nccn.org/patients

Patient Advocate Foundation (PAF)

Direct case management, education and financial support for people living with chronic and debilitating diseases.

Phone: 800-532-5274

www.patientadvocate.org

Prevent Cancer Foundation (PCF)

Nonprofit dedicated to saving lives through cancer prevention and early detection.

Phone (toll-free): 800-227-2732

www.preventcancer.org

disposal icon

Injector Disposal Program

The Sharps Disposal Container Program helps you easily and safely dispose of the On-body Injector for Neulasta® at no additional cost. You can sign up as soon as your doctor prescribes Neulasta® Onpro®. If you have additional questions about the Sharps Disposal Container Program, call 1-844-MYNEULASTA (1-844-696-3852).

Has your doctor prescribed the Neulasta® Onpro® kit which includes the On-body Injector for Neulasta®?

card

Doctor Discussion Guide

Your doctor is there to answer your questions and help you get the most out of your treatment. These questions will help you get the conversation started.

  • What type of chemotherapy am I receiving?
  • How long will I need to use Neulasta®?
  • Am I at risk for infection?
  • Is Neulasta® Onpro® an option for me?
  • What could happen if I get a serious infection?
  • Is Neulasta® or Neulasta® Onpro® covered by my insurance?
  • Should Neulasta® be part of my treatment plan?

Get a printable list of these and other questions to take to your next appointment.

Print List

If you do not have Adobe® Reader®, you can download it for free.

glossary

Glossary of Chemo & Cancer Terms

This list of terms will help you better understand your cancer treatment.

Absolute neutrophil count (ANC) – ANC refers to the total number of neutrophils present in the blood. Neutrophils are particularly important because they defend our bodies against certain types of infection.

Bacteria – Microscopic (can only be seen with a microscope) organisms (living things) that live in and around most living and nonliving things. Some types of bacteria help our bodies stay in balance, while other types can multiply within the body and cause infection. Bacteria are the most common causes of infections in people with cancer. Some examples of bacterial infection include food poisoning, pneumonia, and strep throat.

Chemotherapy (chemo) – Drugs to destroy cancer cells. A person on chemotherapy may take one drug or a combination of drugs. Most often these drugs are given by vein using intravenous (IV) infusion. Some can be taken by mouth or given as an injection, among other methods of delivery.

Co-insurance – Some insurance coverage requires you to pay a percentage of the cost of covered medical services, usually 20–30 percent. Your portion of the cost is the co-insurance.

Colony-stimulating factors – Also called CSFs, colony-stimulating factors are drugs that promote the production of various white blood cells. An example of a CSF is Neulasta® (pegfilgrastim).

Complete blood count (CBC) – The CBC is a test that determines the number of red blood cells, white blood cells, and platelets in the blood.

Co-payment – Also called co-pay, a flat fee for specified medical services required by some insurers. For example, your insurance provider may require you to pay a $10 co-payment for a doctor visit or a $50 co-payment for a hospital stay.

Deductible – The amount you must pay each year for your medical expenses before your insurance policy starts paying. Deductibles are common in fee-for-service coverage and PPOs.

Febrile neutropenia – Having a low white blood cell count (neutropenia) and a fever (a neutropenic fever). Febrile neutropenia is often a sign of a serious infection. Infection – An invasion of microorganisms such as bacteria or viruses that have the ability to multiply and cause disease.

Lymphoma – Cancer that begins in cells of the lymphatic system (part of the immune system that produces and stores cells that fight infection and disease).

Myelosuppressive chemotherapy – Sometimes called strong chemotherapy, a type of chemotherapy that can lower the number of blood cells in your body. Often, people just use the word myelosuppressive to mean chemotherapy that lowers your number of white blood cells.

Neutropenia – A lower-than-normal number of neutrophils (infection-fighting white blood cells) in the blood. It is a common side effect of some chemotherapy treatments. Doctors check the number of neutrophils when they measure the white blood cell count, to monitor the risk of infection.

Neutropenic fever – Having a low white blood cell count with a fever may be a sign of serious infection.

Neutrophil – The most common type of white blood cell. Neutrophils help the body fight infection. A low white blood cell count usually indicates that the neutrophil count is low. It is easier to get an infection and harder to recover from an infection when the number of neutrophils in the bloodstream is low.

Neutrophil count – The number of a specific kind of infection-fighting white blood cells called neutrophils in the blood. A low white blood cell count usually indicates that the neutrophil count is low. It is easier to get an infection and harder to recover from an infection when the number of neutrophils in the bloodstream is low.

Oncologist – A doctor who specializes in the treatment of cancer.

Placebo – A "dummy" treatment used in some clinical trials. In these studies, a group of patients who are given a placebo treatment are compared to another group of patients who are given the actual treatment. The difference in results between the actual treatment group and the placebo group are considered the result of giving the medicine.

Platelets – A type of cell made in the bone marrow. The main function of platelets is to aid in clotting the blood following an injury.

Side effect – Any undesired actions or effects of a drug or treatment. For example, common side effects of chemotherapy include fatigue, nausea, vomiting, and loss of appetite.

White blood cell (WBC) – A white blood cell is one of the three main types of blood cells. They are produced in the bone marrow and released into the blood. White blood cells are responsible for fighting infection. There are several kinds of white blood cells, including monocytes, lymphocytes, neutrophils, eosinophils, and basophils.

Important Safety Information

Do not take Neulasta® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Before you receive Neulasta®, tell your healthcare provider about all of your healthcare conditions, including if you:

  • Have a sickle cell disorder
  • Have had severe skin reactions to acrylic adhesive
  • Are allergic to latex – The needle cap on the prefilled syringe contains dry natural rubber (derived from latex).
  • Have kidney problems
  • Are pregnant or plan to become pregnant. It is not known if Neulasta® may harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if Neulasta® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible serious side effects of Neulasta®?

  • Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta®. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or left shoulder tip area.
  • A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Neulasta® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating.

If you have an allergic reaction during the delivery of Neulasta®, remove the on-body-injector for Neulasta® by grabbing the edge of the adhesive pad and peeling off the on-body-injector. Get emergency medical help right away.

  • Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Neulasta®.
  • Kidney injury (glomerulonephritis). Neulasta® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual.
  • Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Neulasta®.
  • Capillary Leak Syndrome. Neulasta® can cause fluid to leak from blood vessels into your body’s tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
    • swelling or puffiness and are urinating less than usual
    • trouble breathing
    • swelling of your stomach area (abdomen) and feeling of fullness
    • dizziness or feeling faint
    • a general feeling of tiredness
  • Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received Neulasta®. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of Neulasta® is pain in your bones and in your arms and legs.

These are not all the possible side effects of Neulasta®. Call your healthcare provider for medical advice about side effects. You may report negative side effects to the FDA at 1-800-FDA-1088.

Please see Neulasta® Patient Information.

Important Safety Information
Do not take take Neulasta® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.
Before you receive Neulasta®, tell your healthcare provider about all of your healthcare conditions, including if you:
• Have a sickle cell disorder
• Have had severe skin reactions to acrylic adhesive

See More